MIRA制药公司口服氯胺酮类比,Ketamir-2,在神经病痛缓解临床预科研究中优于Gabapentin和Pregabalin。 MIRA Pharmaceuticals' oral ketamine analog, Ketamir-2, outperforms Gabapentin and Pregabalin in preclinical studies for neuropathic pain relief.

MIRA制药公司透露,其口服氯胺酮类比Ketamir-2超过了林业发展局在临床前研究中批准的Gabapentin和Pregabalin药物,以缓解神经病痛。 MIRA Pharmaceuticals has revealed that its oral ketamine analog, Ketamir-2, surpassed FDA-approved medications Gabapentin and Pregabalin in preclinical studies for neuropathic pain relief. 这种非类阿片治疗表现出希望,没有吸毒成瘾或严重副作用的风险。 This non-opioid treatment shows promise without the risk of addiction or severe side effects. MIRA计划到年底提交一份调查性新药物应用软件,并在2025年初启动第一阶段临床试验。 MIRA plans to submit an Investigational New Drug application by year-end and initiate Phase 1 clinical trials in early 2025.